Current Colorectal Cancer Reports

, Volume 10, Issue 4, pp 442–452 | Cite as

Mechanisms by Which Pleiotropic Amphiphilic n−3 PUFA Reduce Colon Cancer Risk

  • Robert S. ChapkinEmail author
  • Vanessa DeClercq
  • Eunjoo Kim
  • Natividad Roberto Fuentes
  • Yang-Yi Fan
Molecular Biology (S Anant, Section Editor)


Colorectal cancer is one of the major causes of cancer-related mortality in both men and women worldwide. Genetic susceptibility and diet are primary determinants of cancer risk and tumor behavior. Experimental, epidemiological, and clinical data substantiate the beneficial role of n−3 polyunsaturated fatty acids (PUFA) in preventing chronic inflammation and colon cancer. From a mechanistic perspective, n−3 PUFA are pleiotropic and multifaceted with respect to their molecular mechanisms of action. For example, this class of dietary lipid uniquely alters membrane structure/cytoskeletal function, impacting membrane receptor function and downstream signaling cascades, including gene expression profiles and cell phenotype. In addition, n−3 PUFA can synergize with other potential anti-tumor agents, such as fermentable fiber and curcumin. With the rising prevalence of diet-induced obesity, there is also an urgent need to elucidate the link between chronic inflammation in adipose tissue and colon cancer risk in obesity. In this review, we will summarize recent developments linking n−3 PUFA intake, membrane alterations, epigenetic modulation, and effects on obesity-associated colon cancer risk.


(n−3) PUFA Colon cancer Membrane rafts Cytoskeleton Epigenetics Obesity 



This work was supported by the American Institute for Cancer Research (AICR); Cancer Prevention and Research Institute of Texas (CPRIT); National Institutes of Health grants CA129444, CA168312, and P30ES023512; and USDA–NIFA Grant Designing Foods for Health 2010-34402-20875. The authors would also like to thank Tim Hou for formatting assistance.

Compliance with Ethics Guidelines

Conflict of Interest

Robert S. Chapkin, Vanessa DeClercq, Eunjoo Kim, Natividad Roberto Fuentes, and Yang-Yi Fan declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 2012;62(5):283–98.PubMedGoogle Scholar
  3. 3.
    Colditz GA, Sellers TA, Trapido E. Epidemiology—identifying the causes and preventability of cancer? Nat Rev Cancer. 2006;6(1):75–83.PubMedGoogle Scholar
  4. 4.
    Vargas AJ, Thompson PA. Diet and nutrient factors in colorectal cancer risk. Nutr Clin Pract. 2012;27(5):613–23.PubMedGoogle Scholar
  5. 5.
    Ben Q, Sun Y, Chai R, Qian A, Xu B, Yuan Y. Dietary fiber intake reduces risk for colorectal adenoma: a meta-analysis. Gastroenterology. 2014;146(3):689–99. e6.PubMedGoogle Scholar
  6. 6.
    Zhang J, Zhang L, Ye X, Chen L, Zhang L, Gao Y, et al. Characteristics of fatty acid distribution is associated with colorectal cancer prognosis. Prostaglandins Leukot Essent Fatty Acids. 2013;88(5):355–60.PubMedGoogle Scholar
  7. 7.
    Guesnet P, Alessandri JM. Docosahexaenoic acid (DHA) and the developing central nervous system (CNS)—implications for dietary recommendations. Biochimie. 2011;93(1):7–12.PubMedGoogle Scholar
  8. 8.
    Davidson LA, Wang N, Shah MS, Lupton JR, Ivanov I, Chapkin RS. n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis. 2009;30(12):2077–84.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Hull MA. Omega-3 polyunsaturated fatty acids. Best Pract Res Clin Gastroenterol. 2011;25(4–5):547–54.PubMedGoogle Scholar
  10. 10.
    Cho Y, Turner ND, Davidson LA, Chapkin RS, Carroll RJ, Lupton JR. A chemoprotective fish oil/pectin diet enhances apoptosis via Bcl-2 promoter methylation in rat azoxymethane-induced carcinomas. Exp Biol Med (Maywood). 2012;237(12):1387–93.Google Scholar
  11. 11.
    Jing K, Wu T, Lim K. Omega-3 polyunsaturated fatty acids and cancer. Anticancer Agents Med Chem. 2013;13(8):1162–77.PubMedGoogle Scholar
  12. 12.
    Horejsi V, Hrdinka M. Membrane microdomains in immunoreceptor signaling. FEBS Lett. 2014Google Scholar
  13. 13.
    Pike LJ. Lipid rafts: bringing order to chaos. J Lipid Res. 2003;44(4):655–67.PubMedGoogle Scholar
  14. 14.•
    Head BP, Patel HH, Insel PA. Interaction of membrane/lipid rafts with the cytoskeleton: impact on signaling and function: membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling. Biochim Biophys Acta. 2014;1838(2):532–45. The dynamic interaction of membrane lipid rafts and the cytoskeleton are discussed with respect to cell phenotype.PubMedGoogle Scholar
  15. 15.
    Hazarika P, McCarty MF, Prieto VG, George S, Babu D, Koul D, et al. Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res. 2004;64(20):7361–9.PubMedGoogle Scholar
  16. 16.
    Li YC, Park MJ, Ye SK, Kim CW, Kim YN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 2006;168(4):1107–18. quiz 404–5.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Patra SK. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta. 2008;1785(2):182–206.PubMedGoogle Scholar
  18. 18.
    Fedida-Metula S, Feldman B, Koshelev V, Levin-Gromiko U, Voronov E, Fishman D. Lipid rafts couple store-operated Ca2+ entry to constitutive activation of PKB/Akt in a Ca2+/calmodulin-, Src- and PP2A-mediated pathway and promote melanoma tumor growth. Carcinogenesis. 2012;33(4):740–50.PubMedGoogle Scholar
  19. 19.
    Lasserre R, Guo XJ, Conchonaud F, Hamon Y, Hawchar O, Bernard AM, et al. Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol. 2008;4(9):538–47.PubMedGoogle Scholar
  20. 20.
    Roy UK, Rial NS, Kachel KL, Gerner EW. Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis. Mol Carcinog. 2008;47(7):538–53.PubMedGoogle Scholar
  21. 21.
    Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol. 2011;226(9):2316–28.PubMedPubMedCentralGoogle Scholar
  22. 22.
    George KS, Wu S. Lipid raft: a floating island of death or survival. Toxicol Appl Pharmacol. 2012;259(3):311–9.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Lacour S, Hammann A, Grazide S, Lagadic-Gossmann D, Athias A, Sergent O, et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 2004;64(10):3593–8.PubMedGoogle Scholar
  24. 24.
    Rebillard A, Tekpli X, Meurette O, Sergent O, LeMoigne-Muller G, Vernhet L, et al. Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. Cancer Res. 2007;67(16):7865–74.PubMedGoogle Scholar
  25. 25.
    Adachi S, Nagao T, Ingolfsson HI, Maxfield FR, Andersen OS, Kopelovich L, et al. The inhibitory effect of (−)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res. 2007;67(13):6493–501.PubMedGoogle Scholar
  26. 26.
    Bacso Z, Bene L, Damjanovich L, Damjanovich S. INF-gamma rearranges membrane topography of MHC-I and ICAM-1 in colon carcinoma cells. Biochem Biophys Res Commun. 2002;290(2):635–40.PubMedGoogle Scholar
  27. 27.•
    Gelsomino G, Corsetto PA, Campia I, Montorfano G, Kopecka J, Castella B, et al. Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. Mol Cancer. 2013;12:137. This cell culture based study provides evidence implicating omega 3 PUFA with lipid rafts and chemosensitivity.PubMedGoogle Scholar
  28. 28.
    Ma DW, Seo J, Davidson LA, Callaway ES, Fan YY, Lupton JR, et al. n-3 PUFA alter caveolae lipid composition and resident protein localization in mouse colon. FASEB J. 2004;18(9):1040–2.PubMedGoogle Scholar
  29. 29.
    Fan Y-Y, McMurray DN, Ly LH, Chapkin RS. Dietary (n-3) polyunsaturated fatty acids remodel mouse T-cell lipid rafts. J Nutr. 2003;133(6):1913–20.Google Scholar
  30. 30.
    Chapkin RS, Wang N, Fan YY, Lupton JR, Prior IA. Docosahexaenoic acid alters the size and distribution of cell surface microdomains. Biochim Biophys Acta. 2008;1778(2):466–71Google Scholar
  31. 31.
    Shaikh SR, Cherezov V, Caffrey M, Soni SP, LoCascio D, Stillwell W, et al. Molecular organization of cholesterol in unsaturated phosphatidylethanolamines: X-ray diffraction and solid state 2H NMR reveal differences with phosphatidylcholines. J Am Chem Soc. 2006;128(16):5375–83.PubMedGoogle Scholar
  32. 32.
    Brzustowicz MR, Cherezov V, Caffrey M, Stillwell W, Wassall SR. Molecular organization of cholesterol in polyunsaturated membranes: microdomain formation. Biophys J. 2002;82(1 Pt 1):285–98.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009;69(8):3382–9.PubMedPubMedCentralGoogle Scholar
  34. 34.••
    Shaikh SR, Kinnun JJ, Leng X, Williams JA, Wassall SR. How polyunsaturated fatty acids modify molecular organization in membranes: insight from NMR studies of model systems. Biochim Biophys Acta. 2014. The effects of long chain polyunsaturated fatty acids with respect to the biophysical properties of membranes is discussed.Google Scholar
  35. 35.
    Owen DM, Rentero C, Magenau A, Abu-Siniyeh A, Gaus K. Quantitative imaging of membrane lipid order in cells and organisms. Nat Protoc. 2012;7(1):24–35.Google Scholar
  36. 36.
    Gaus K, Zech T, Harder T. Visualizing membrane microdomains by Laurdan 2-photon microscopy. Mol Membr Biol. 2006;23(1):41–8.PubMedGoogle Scholar
  37. 37.
    Kim W, Fan YY, Barhoumi R, Smith R, McMurray DN, Chapkin RS. n-3 polyunsaturated fatty acids suppress the localization and activation of signaling proteins at the immunological synapse in murine CD4+ T cells by affecting lipid raft formation. J Immunol. 2008;181(9):6236–43.PubMedPubMedCentralGoogle Scholar
  38. 38.••
    Kim W, Barhoumi R, McMurray DN, Chapkin RS. Dietary fish oil and DHA down-regulate antigen-activated CD4+ T-cells while promoting the formation of liquid-ordered mesodomains. Br J Nutr. 2014;111(2):254–60. Compelling evidence is provided indicating that n-3 PUFA from distinct dietary sources can be integrated into antigen activated CD4+ T-cells, resulting in the modulation of plasma membrane order and translocation of signaling kinases to the immunological synapse.PubMedGoogle Scholar
  39. 39.
    Rockett BD, Teague H, Harris M, Melton M, Williams J, Wassall SR, et al. Fish oil increases raft size and membrane order of B cells accompanied by differential effects on function. J Lipid Res. 2012;53(4):674–85.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Zech T, Ejsing CS, Gaus K, de Wet B, Shevchenko A, Simons K, et al. Accumulation of raft lipids in T-cell plasma membrane domains engaged in TCR signalling. EMBO J. 2009;28(5):466–76.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Kim W, Khan NA, McMurray DN, Prior IA, Wang N, Chapkin RS. Regulatory activity of polyunsaturated fatty acids in T-cell signaling. Prog Lipid Res. 2010;49(3):250–61.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell. 2010;140(6):771–6.PubMedGoogle Scholar
  43. 43.
    Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J. The soluble interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol. 2011;90(6–7):484–94.PubMedGoogle Scholar
  45. 45.
    Prior IA, Muncke C, Parton RG, Hancock JF. Direct visualization of Ras proteins in spatially distinct cell surface microdomains. J Cell Biol. 2003;160(2):165–70.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21–6.PubMedGoogle Scholar
  47. 47.
    Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012;18(2):221–3.PubMedGoogle Scholar
  48. 48.
    Pike LJ. Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta. 2005;1746(3):260–73.PubMedGoogle Scholar
  49. 49.
    Ringerike T, Blystad FD, Levy FO, Madshus IH, Stang E. Cholesterol is important in control of EGF receptor kinase activity but EGF receptors are not concentrated in caveolae. J Cell Sci. 2002;115(Pt 6):1331–40.PubMedGoogle Scholar
  50. 50.
    Rogers KR, Kikawa KD, Mouradian M, Hernandez K, McKinnon KM, Ahwah SM, et al. Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association. Carcinogenesis. 2010;31(9):1523–30.PubMedGoogle Scholar
  51. 51.
    Schley PD, Brindley DN, Field CJ. (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. J Nutr. 2007;137(3):548–53.PubMedGoogle Scholar
  52. 52.••
    Turk HF, Barhoumi R, Chapkin RS. Alteration of EGFR spatiotemporal dynamics suppresses signal transduction. PLoS One. 2012;7(6):e39682. DHA-induced alteration in both the lateral and subcellular localization of EGFR culminates in the suppression of downstream signal transduction, which has implications for the molecular basis of colon cancer prevention.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Stulnig TM, Huber J, Leitinger N, Imre EM, Angelisova P, Nowotny P, et al. Polyunsaturated eicosapentaenoic acid displaces proteins from membrane rafts by altering raft lipid composition. J Biol Chem. 2001;276(40):37335–40.PubMedGoogle Scholar
  54. 54.
    Zeyda M, Staffler G, Horejsi V, Waldhausl W, Stulnig TM. LAT displacement from lipid rafts as a molecular mechanism for the inhibition of T cell signaling by polyunsaturated fatty acids. J Biol Chem. 2002;277(32):28418–23.PubMedGoogle Scholar
  55. 55.
    Eisenberg S, Laude AJ, Beckett AJ, Mageean CJ, Aran V, Hernandez-Valladares M, et al. The role of palmitoylation in regulating Ras localization and function. Biochem Soc Trans. 2013;41(1):79–83.PubMedGoogle Scholar
  56. 56.
    Seo J, Barhoumi R, Johnson AE, Lupton JR, Chapkin RS. Docosahexaenoic acid selectively inhibits plasma membrane targeting of lipidated proteins. FASEB J. 2006;20(6):770–2.PubMedGoogle Scholar
  57. 57.
    Krasinskas AM. EGFR signaling in colorectal carcinoma. Patholog Res Int. 2011;2011:932932.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell. 2014;25(3):272–81.PubMedGoogle Scholar
  59. 59.
    Sawan C, Vaissiere T, Murr R, Herceg Z. Epigenetic drivers and genetic passengers on the road to cancer. Mutat Res. 2008;642(1–2):1–13.PubMedGoogle Scholar
  60. 60.
    Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21(1):103–7.PubMedGoogle Scholar
  61. 61.
    Davis CD, Ross SA. Dietary components impact histone modifications and cancer risk. Nutr Rev. 2007;65(2):88–94.PubMedGoogle Scholar
  62. 62.
    Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009;1(2):239–59.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27–56.PubMedGoogle Scholar
  64. 64.
    Mani S, Herceg Z. DNA demethylating agents and epigenetic therapy of cancer. Adv Genet. 2010;70:327–40.PubMedGoogle Scholar
  65. 65.
    Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693–705.PubMedGoogle Scholar
  66. 66.
    Sawan C, Herceg Z. Histone modifications and cancer. Adv Genet. 2010;70:57–85.PubMedGoogle Scholar
  67. 67.
    Steger DJ, Workman JL. Remodeling chromatin structures for transcription: what happens to the histones? Bioessays. 1996;18(11):875–84.PubMedGoogle Scholar
  68. 68.
    Zhang K, Dent SY. Histone modifying enzymes and cancer: going beyond histones. J Cell Biochem. 2005;96(6):1137–48.PubMedGoogle Scholar
  69. 69.
    Fabbri M, Calin GA. Epigenetics and miRNAs in human cancer. Adv Genet. 2010;70:87–99.PubMedGoogle Scholar
  70. 70.
    Vandenboom Ii TG, Li Y, Philip PA, Sarkar FH. MicroRNA and cancer: tiny molecules with major implications. Curr Genomics. 2008;9(2):97–109.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Winter J, Diederichs S. MicroRNA biogenesis and cancer. Methods Mol Biol. 2011;676:3–22.PubMedGoogle Scholar
  72. 72.
    Davidson LA, Nguyen DV, Hokanson RM, Callaway ES, Isett RB, Turner ND, et al. Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat. Cancer Res. 2004;64(18):6797–804.PubMedGoogle Scholar
  73. 73.
    Davidson LA, Wang N, Ivanov I, Goldsby J, Lupton JR, Chapkin RS. Identification of actively translated mRNA transcripts in a rat model of early-stage colon carcinogenesis. Cancer Prev Res (Phila). 2009;2(11):984–94.Google Scholar
  74. 74.
    Piepoli A, Tavano F, Copetti M, Mazza T, Palumbo O, Panza A, et al. Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One. 2012;7(3):e33663.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009;8:102.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007;72(5–6):397–402.PubMedGoogle Scholar
  77. 77.
    Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27(15):2128–36.PubMedGoogle Scholar
  78. 78.
    Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko Jr RJ, et al. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 2009;69(20):8157–65.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Kim YJ, Hwang SJ, Bae YC, Jung JS. MiR-21 regulates adipogenic differentiation through the modulation of TGF-beta signaling in mesenchymal stem cells derived from human adipose tissue. Stem Cells. 2009;27(12):3093–102.PubMedGoogle Scholar
  80. 80.
    Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene. 2008;27(31):4373–9.PubMedGoogle Scholar
  81. 81.
    Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647–58.PubMedGoogle Scholar
  82. 82.
    Shi L, Chen J, Yang J, Pan T, Zhang S, Wang Z. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 2010;1352:255–64.PubMedGoogle Scholar
  83. 83.
    Song B, Wang C, Liu J, Wang X, Lv L, Wei L, et al. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res. 2010;29:29.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 2009;37(8):2584–95.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W, et al. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest. 2008;88(12):1358–66.PubMedGoogle Scholar
  86. 86.
    Zhou X, Zhang J, Jia Q, Ren Y, Wang Y, Shi L, et al. Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3. Oncol Rep. 2010;24(1):195–201.PubMedGoogle Scholar
  87. 87.
    Kolar SS, Barhoumi R, Callaway ES, Fan YY, Wang N, Lupton JR, et al. Synergy between docosahexaenoic acid and butyrate elicits p53-independent apoptosis via mitochondrial Ca(2+) accumulation in colonocytes. Am J Physiol Gastrointest Liver Physiol. 2007;293(5):G935–43.PubMedGoogle Scholar
  88. 88.
    Kolar SS, Barhoumi R, Lupton JR, Chapkin RS. Docosahexaenoic acid and butyrate synergistically induce colonocyte apoptosis by enhancing mitochondrial Ca2+ accumulation. Cancer Res. 2007;67(11):5561–8.PubMedGoogle Scholar
  89. 89.
    Vanamala J, Glagolenko A, Yang P, Carroll RJ, Murphy ME, Newman RA, et al. Dietary fish oil and pectin enhance colonocyte apoptosis in part through suppression of PPARdelta/PGE2 and elevation of PGE3. Carcinogenesis. 2008;29(4):790–6.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Chen Y, Shu W, Chen W, Wu Q, Liu H, Cui G. Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. Basic Clin Pharmacol Toxicol. 2007;101(6):427–33.PubMedGoogle Scholar
  91. 91.
    Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer. 2010;116(20):4670–6.PubMedGoogle Scholar
  92. 92.
    Liu HL, Chen Y, Cui GH, Zhou JF. Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacol Sin. 2005;26(5):603–9.PubMedGoogle Scholar
  93. 93.
    Reuter S, Gupta SC, Park B, Goel A, Aggarwal BB. Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr. 2011;6(2):93–108.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Wu Q, Chen Y, Li X. HDAC1 expression and effect of curcumin on proliferation of Raji cells. J Huazhong Univ Sci Technolog Med Sci. 2006;26(2):199–201. 10.PubMedGoogle Scholar
  95. 95.
    Ye MX, Li Y, Yin H, Zhang J. Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int J Mol Sci. 2012;13(3):3959–78.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Kelkel M, Jacob C, Dicato M, Diederich M. Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies. Molecules. 2010;15(10):7035–74.PubMedGoogle Scholar
  97. 97.
    Teiten MH, Eifes S, Reuter S, Duvoix A, Dicato M, Diederich M. Gene expression profiling related to anti-inflammatory properties of curcumin in K562 leukemia cells. Ann N Y Acad Sci. 2009;1171:391–8.PubMedGoogle Scholar
  98. 98.
    Reuter S, Charlet J, Juncker T, Teiten MH, Dicato M, Diederich M. Effect of curcumin on nuclear factor kappaB signaling pathways in human chronic myelogenous K562 leukemia cells. Ann N Y Acad Sci. 2009;1171:436–47.PubMedGoogle Scholar
  99. 99.
    Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008;269(2):199–225.PubMedGoogle Scholar
  100. 100.
    Jia Q, Ivanov I, Zlatev ZZ, Alaniz RC, Weeks BR, Callaway ES, et al. Dietary fish oil and curcumin combine to modulate colonic cytokinetics and gene expression in dextran sodium sulphate-treated mice. Br J Nutr. 2011;106(4):519–29.PubMedGoogle Scholar
  101. 101.
    Fenton JI, McCaskey SJ. Curcumin and docosahexaenoic acid block insulin-induced colon carcinoma cell proliferation. Prostaglandins Leukot Essent Fatty Acids. 2013;88(3):219–26.PubMedGoogle Scholar
  102. 102.
    Siddiqui RA, Harvey KA, Walker C, Altenburg J, Xu Z, Terry C, et al. Characterization of synergistic anti-cancer effects of docosahexaenoic acid and curcumin on DMBA-induced mammary tumorigenesis in mice. BMC Cancer. 2013;13:418.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Bordonaro M, Lazarova DL, Sartorelli AC. Butyrate and Wnt signaling: a possible solution to the puzzle of dietary fiber and colon cancer risk? Cell Cycle. 2008;7(9):1178–83.PubMedGoogle Scholar
  104. 104.••
    Fan YY, Davidson LA, Callaway ES, Goldsby JS, Chapkin RS. Differential effects of 2- and 3-series E-prostaglandins on in vitro expansion of Lgr5+ colonic stem cells. Carcinogenesis. 2014;35(3):606–12. Relative to arachidonic acid-derived PGE2, a known promoter of colon tumorigenesis, eicosapentaenoic acid-derived PGE3 has diminished ability to support colonic stem cell expansion in mouse colonic organoids.PubMedGoogle Scholar
  105. 105.
    Fujise T, Iwakiri R, Kakimoto T, Shiraishi R, Sakata Y, Wu B, et al. Long-term feeding of various fat diets modulates azoxymethane-induced colon carcinogenesis through Wnt/beta-catenin signaling in rats. Am J Physiol Gastrointest Liver Physiol. 2007;292(4):G1150–6.PubMedGoogle Scholar
  106. 106.
    Liu Z, Choi SW, Crott JW, Keyes MK, Jang H, Smith DE, et al. Mild depletion of dietary folate combined with other B vitamins alters multiple components of the Wnt pathway in mouse colon. J Nutr. 2007;137(12):2701–8.PubMedGoogle Scholar
  107. 107.
    MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9–26.PubMedPubMedCentralGoogle Scholar
  108. 108.
    Willis ND, Przyborski SA, Hutchison CJ, Wilson RG. Colonic and colorectal cancer stem cells: progress in the search for putative biomarkers. J Anat. 2008;213(1):59–65.PubMedPubMedCentralGoogle Scholar
  109. 109.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.PubMedGoogle Scholar
  110. 110.
    Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev. 2010;11(1):19–30.PubMedGoogle Scholar
  111. 111.
    Ashktorab H, Paydar M, Yazdi S, Namin HH, Sanderson A, Begum R, et al. BMI and the risk of colorectal adenoma in African-Americans. Obesity (Silver Spring). 2014;22(5):1387–91.Google Scholar
  112. 112.
    Endo H, Hosono K, Fujisawa T, Takahashi H, Sugiyama M, Yoneda K, et al. Involvement of JNK pathway in the promotion of the early stage of colorectal carcinogenesis under high-fat dietary conditions. Gut. 2009;58(12):1637–43.PubMedGoogle Scholar
  113. 113.•
    Olivo-Marston SE, Hursting SD, Perkins SN, Schetter A, Khan M, Croce C, et al. Effects of calorie restriction and diet-induced obesity on murine colon carcinogenesis, growth and inflammatory factors, and microRNA expression. PLoS One. 2014;9(4):e94765. Diet-induced obesity and the suppressive effects of calorie restriction on colon carcinogenesis are associated with alterations in non-coding microRNAs.PubMedPubMedCentralGoogle Scholar
  114. 114.
    Sikalidis AK, Fitch MD, Fleming SE. Diet induced obesity increases the risk of colonic tumorigenesis in mice. Pathol Oncol Res. 2013;19(4):657–66.PubMedGoogle Scholar
  115. 115.
    Johnson AR, Milner JJ, Makowski L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev. 2012;249(1):218–38.PubMedPubMedCentralGoogle Scholar
  116. 116.
    Karastergiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol. 2010;318(1–2):69–78.PubMedGoogle Scholar
  117. 117.
    Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–84.PubMedPubMedCentralGoogle Scholar
  118. 118.
    Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes. 2007;56(1):16–23.PubMedGoogle Scholar
  119. 119.••
    Monk JM, Hou TY, Turk HF, Weeks B, Wu C, McMurray DN, et al. Dietary n-3 polyunsaturated fatty acids (PUFA) decrease obesity-associated Th17 cell-mediated inflammation during colitis. PLoS One. 2012;7(11):e49739. n-3 PUFA suppress Th1/Th17 cells and inflammatory macrophage subsets and reconfigure the inflammatory gene expression profile in diverse tissue sites in obese mice following the induction of colitis.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Janakiram NB, Rao CV. The role of inflammation in colon cancer. Adv Exp Med Biol. 2014;816:25–52.PubMedGoogle Scholar
  121. 121.
    Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749–59.PubMedGoogle Scholar
  122. 122.
    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.PubMedGoogle Scholar
  123. 123.
    Famulla S, Lamers D, Hartwig S, Passlack W, Horrighs A, Cramer A, et al. Pigment epithelium-derived factor (PEDF) is one of the most abundant proteins secreted by human adipocytes and induces insulin resistance and inflammatory signaling in muscle and fat cells. Int J Obes (Lond). 2011;35(6):762–72.Google Scholar
  124. 124.
    Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79–83.PubMedGoogle Scholar
  125. 125.
    DeClercq V, Enns JE, Yeganeh A, Taylor CG, Zahradka P. Modulation of cardiovascular function by adipokines. Cardiovasc Hematol Disord Drug Targets. 2013;13(1):59–72.PubMedGoogle Scholar
  126. 126.
    Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci. 2009;30(5):234–9.PubMedGoogle Scholar
  127. 127.
    Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond). 2008;32 Suppl 7:S13–8.Google Scholar
  128. 128.
    Otake S, Takeda H, Fujishima S, Fukui T, Orii T, Sato T, et al. Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol. 2010;16(10):1252–7.PubMedPubMedCentralGoogle Scholar
  129. 129.
    Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97(22):1688–94.PubMedGoogle Scholar
  130. 130.
    Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res. 2010;70(13):5430–7.PubMedGoogle Scholar
  131. 131.
    Fenton JI, Birmingham JM. Adipokine regulation of colon cancer: adiponectin attenuates interleukin-6-induced colon carcinoma cell proliferation via STAT-3. Mol Carcinog. 2010;49(7):700–9.PubMedPubMedCentralGoogle Scholar
  132. 132.
    Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, Saito S, et al. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut. 2008;57(11):1531–8.PubMedPubMedCentralGoogle Scholar
  133. 133.
    Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol. 2010;24(7):1441–52.PubMedGoogle Scholar
  134. 134.•
    Moon HS, Liu X, Nagel JM, Chamberland JP, Diakopoulos KN, Brinkoetter MT, et al. Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut. 2013;62(4):561–70. Adipose-derived adipokines are directly implicated in colon cancer risk.PubMedGoogle Scholar
  135. 135.
    Pan H, Guo J, Su Z. Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav. 2014;130:157–69.PubMedGoogle Scholar
  136. 136.
    Chia VM, Newcomb PA, Lampe JW, White E, Mandelson MT, McTiernan A, et al. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2697–703.PubMedGoogle Scholar
  137. 137.
    Birmingham JM, Busik JV, Hansen-Smith FM, Fenton JI. Novel mechanism for obesity-induced colon cancer progression. Carcinogenesis. 2009;30(4):690–7.PubMedPubMedCentralGoogle Scholar
  138. 138.
    Endo H, Hosono K, Uchiyama T, Sakai E, Sugiyama M, Takahashi H, et al. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut. 2011;60(10):1363–71.PubMedGoogle Scholar
  139. 139.
    Padidar S, Farquharson AJ, Williams LM, Kelaiditi E, Hoggard N, Arthur JR, et al. Leptin up-regulates pro-inflammatory cytokines in discrete cells within mouse colon. J Cell Physiol. 2011;226(8):2123–30.PubMedGoogle Scholar
  140. 140.
    Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res. 2010;70(13):5430–7.PubMedGoogle Scholar
  141. 141.
    Fenton JI, Birmingham JM, Hursting SD, Hord NG. Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Apc Min/+colon epithelial cells. Int J Cancer. 2008;122(11):2437–45.PubMedGoogle Scholar
  142. 142.
    Li Y, Wang L, Pappan L, Galliher-Beckley A, Shi J. IL-1beta promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Mol Cancer. 2012;11:87.PubMedPubMedCentralGoogle Scholar
  143. 143.
    Wang L, Liu Z, Li Y, Pappan L, Galliher-Beckley A, Shi J. Pro-inflammatory cytokine interleukin-1beta promotes the development of intestinal stem cells. Inflamm Res. 2012;61(10):1085–92.PubMedGoogle Scholar
  144. 144.
    Hyun YS, Han DS, Lee AR, Eun CS, Youn J, Kim HY. Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis. 2012;33(4):931–6.PubMedGoogle Scholar
  145. 145.
    Hillenbrand A, Fassler J, Huber N, Xu P, Henne-Bruns D, Templin M et al. Changed adipocytokine concentrations in colorectal tumor patients and morbidly obese patients compared to healthy controls. BMC cancer. 2012;12:545–2407–12–545.Google Scholar
  146. 146.••
    Itariu BK, Zeyda M, Hochbrugger EE, Neuhofer A, Prager G, Schindler K, et al. Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial. Am JClin Nutr. 2012;96(5):1137–49. Treatment with long-chain n-3 PUFAs favorably modulated adipose tissue and systemic inflammation in severely obese non-diabetic patients and improved lipid metabolism.Google Scholar
  147. 147.
    Jilkova ZM, Hensler M, Medrikova D, Janovska P, Horakova O, Rossmeisl M, et al. Adipose tissue-related proteins locally associated with resolution of inflammation in obese mice. Int J Obes (Lond). 2014;38(2):216–23.Google Scholar
  148. 148.
    Kuda O, Jelenik T, Jilkova Z, Flachs P, Rossmeisl M, Hensler M, et al. n-3 fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet. Diabetologia. 2009;52(5):941–51.PubMedGoogle Scholar
  149. 149.
    Jia Q, Lupton JR, Smith R, Weeks BR, Callaway E, Davidson LA, et al. Reduced colitis-associated colon cancer in fat-1 (n-3 fatty acid desaturase) transgenic mice. Cancer Res. 2008;68(10):3985–91.PubMedPubMedCentralGoogle Scholar
  150. 150.
    Nowak J, Weylandt KH, Habbel P, Wang J, Dignass A, Glickman JN, et al. Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids. Carcinogenesis. 2007;28(9):1991–5.PubMedGoogle Scholar
  151. 151.
    Rao CV, Hirose Y, Indranie C, Reddy BS. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res. 2001;61(5):1927–33.PubMedGoogle Scholar
  152. 152.••
    D’Archivio M, Scazzocchio B, Giammarioli S, Fiani ML, Vari R, Santangelo C, et al. Omega 3-PUFAs exert anti-inflammatory activity in visceral adipocytes from colorectal cancer patients. PLoS One. 2013;8(10):e77432. Adipocyte dysfunction occurs in colon cancer patients creating a pro-inflammatory environment that might influence cancer development. The protective potential of DHA in re-establishing the equilibrium between pro- and anti-inflammatory factors is documented.PubMedPubMedCentralGoogle Scholar
  153. 153.
    Chapkin RS, McMurray DN, Lupton JR. Colon cancer, fatty acids and anti-inflammatory compounds. Curr Opin Gastroenterol. 2007;23(1):48–54.PubMedGoogle Scholar
  154. 154.
    Cheng J, Ogawa K, Kuriki K, Yokoyama Y, Kamiya T, Seno K, et al. Increased intake of n-3 polyunsaturated fatty acids elevates the level of apoptosis in the normal sigmoid colon of patients polypectomized for adenomas/tumors. Cancer Lett. 2003;193(1):17–24.PubMedGoogle Scholar
  155. 155.
    Cockbain AJ. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut. 2012;61(1):135–49.PubMedGoogle Scholar
  156. 156.
    Courtney ED. Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas. Int J Color Dis. 2007;22(7):765–76.Google Scholar
  157. 157.
    Turk HF, Monk JM, Fan YY, Callaway ES, Weeks B, Chapkin RS. Inhibitory effects of omega-3 fatty acids on injury induced epidermal growth factor transactivation contribute to delayed wound healing. Am J Physiol Cell Physiol. 2013;304(9):C905–17.PubMedPubMedCentralGoogle Scholar
  158. 158.
    Lien EL. Toxicology and safety of DHA. Prostaglandins Leukot Essent Fatty Acids. 2009;81(2–3):125–32.PubMedGoogle Scholar
  159. 159.
    Bell GA, Kantor ED, Lampe JW, Kristal AR, Heckbert SR, White E. Intake of long-chain omega-3 fatty acids from diet and supplements in relation to mortality. Am J Epidemiol. 2014;179(6):710–20.PubMedGoogle Scholar
  160. 160.••
    Hou TY, Monk JM, Fan YY, Barhoumi R, Chen YQ, Rivera GM, et al. n-3 polyunsaturated fatty acids suppress phosphatidylinositol 4,5-bisphosphate-dependent actin remodelling during CD4+ T-cell activation. Biochem J. 2012;443(1):27–37. Cogent evidence demonstrates for the first time that DHA modulates PI(4,5)P2-dependent actin remodeling by decreasing steady-state PI(4,5)P2 levels. These findings highlight a novel modality by which n-3 PUFA influence membrane organization, thereby modulating biological responses.PubMedGoogle Scholar
  161. 161.
    Mate S, Busto JV, Garcia-Arribas AB, Sot J, Vazquez R, Herlax V, et al. N-Nervonoylsphingomyelin (c24:1) prevents lateral heterogeneity in cholesterol-containing membranes. Biophys J. 2014;106(12):2606–16.PubMedGoogle Scholar
  162. 162.
    Rajamoorthi K, Petrache HI, McIntosh TJ, Brown MF. Packing and viscoelasticity of polyunsaturated omega-3 and omega-6 lipid bilayers as seen by (2)H NMR and X-ray diffraction. J Am Chem Soc. 2005;127(5):1576–88.PubMedGoogle Scholar
  163. 163.
    Shah MS, Schwartz SL, Zhao C, Davidson LA, Zhou B, Lupton JR, et al. Integrated microRNA and mRNA expression profiling in a rat colon carcinogenesis model: effect of a chemo-protective diet. Physiol Genomics. 2011;43(10):640–54.PubMedPubMedCentralGoogle Scholar
  164. 164.
    Gil-Zamorano J, Martin R, Daimiel L, Richardson K, Giordano E, Nicod N, et al. Docosahexaenoic acid modulates the enterocyte Caco-2 cell expression of microRNAs involved in lipid metabolism. J Nutr. 2014;144(5):575–85.PubMedGoogle Scholar
  165. 165.
    Sun H, Meng X, Han J, Zhang Z, Wang B, Bai X, et al. Anti-cancer activity of DHA on gastric cancer—an in vitro and in vivo study. Tumour Biol. 2013;34(6):3791–800.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Robert S. Chapkin
    • 1
    • 2
    • 3
    • 4
    • 6
    Email author
  • Vanessa DeClercq
    • 1
    • 3
  • Eunjoo Kim
    • 1
    • 5
  • Natividad Roberto Fuentes
    • 1
    • 6
  • Yang-Yi Fan
    • 1
    • 3
  1. 1.Program in Integrative Nutrition and Complex DiseasesTexas A&M UniversityCollege StationUSA
  2. 2.Center for Translational Environmental Health ResearchTexas A&M UniversityCollege StationUSA
  3. 3.Department of Nutrition and Food ScienceTexas A&M UniversityCollege StationUSA
  4. 4.Biochemistry & BiophysicsTexas A&M UniversityCollege StationUSA
  5. 5.Molecular & Cellular MedicineTexas A&M UniversityCollege StationUSA
  6. 6.Faculty of ToxicityTexas A&M UniversityCollege StationUSA

Personalised recommendations